MRI software company Acuitas Medical of Swansea, U.K., successfully obtained another round of investment funding, reaching seven figures, which exceeded its financial objectives.
The funds will be used to accelerate its clinical validation and workflow integration programs with disease signature biomarkers for liver, lung, brain, and bone pathologies.
Acuitas Medical's fineSA software provides an add-on sequence to standard MRI, enabling soft-tissue structures to be sampled at up to 40 times the spatial resolution of conventional MR imaging. FineSA data can be acquired in as few as 15 seconds, according to the company.
Research conducted by Dr. Juliet Compston, a professor of bone medicine and honorary consultant physician at the University of Cambridge Department of Medicine at Addenbrooke's Hospital in Cambridge, and Dr. Diego Martin, head of the department of radiology at the University of Arizona College of Medicine-Tucson, have demonstrated the potential for the early diagnosis of liver fibrosis and osteoporosis, the company said.
Acuitas Medical, which was the recipient of the 2010 Minnies Award for Best New Radiology Vendor, will showcase its work-in-progress fineSA technology at the RSNA Quantitative Imaging Reading Room during the annual meeting in Chicago, starting 27 on November.
